Rethinking Lung Cancer Screening Paradigms

As physicians, we are guided by data, evidence-based guidelines, and a commitment to early detection. Yet, a growing clinical phenomenon—the incidental finding of early-stage lung cancer—suggests a significant gap in our current screening paradigm. A recent case at our institution is illustrative: a woman aged 70 years, with a smoking cessation history of over 50 years, underwent a routine cardiac calcium scan. This non–lung-focused imaging incidentally revealed a pulmonary nodule, which, upon follow-up and surgical resection, was confirmed to be a stage IA adenocarcinoma. This patient, whose cancer was eminently treatable due to its early discovery, falls well outside the current US Preventive Services Task Force (USPSTF) screening criteria.

Her case is not an anomaly but rather a sentinel event, representative of a cohort we are increasingly encountering. Studies corroborate this, with some estimates suggesting that up to two-thirds of surgically resected lung cancers are now discovered incidentally rather than through intentional screening.¹ This reliance on serendipity for the nation's leading cause of cancer death is an untenable strategy. Although adherence to screening for breast and colorectal cancers is robust, lung cancer screening languishes, with only an estimated 20% of eligible patients participating.² The issue is 2-fold: overcoming barriers for the eligible and, more critically, questioning the very definition of eligibility. The current USPSTF guidelines—requiring a 20 pack-year history for adults aged 50 to 80 years who currently smoke or have quit within the past 15 years—inherently exclude a significant and growing population of at-risk individuals, including long-term former smokers, those with occupational exposures, and certain ethnic groups with a higher predisposition to lung cancer, irrespective of smoking history.

From a surgical standpoint, the implications are profound. The evolution of minimally invasive techniques, including robotic and video-assisted thoracoscopic surgery, combined with lung-sparing operations such as segmentectomy, enables parenchymal-sparing resections for these early-stage tumors, leading to excellent oncologic outcomes with significantly reduced morbidity and improved quality of life. Finding these cancers at earlier stages is a paradigm shift in management. However, we can only offer these curative-intent procedures if the cancers are discovered. We are surgically equipped for a battle we are too often not alerted to until the later stages, when the chances of a cure are much lower.

This diagnostic challenge is being met with a technological opportunity. The advent of photon-counting CT scanners, such as the Naeotom Alpha, represents a pivotal advancement. This technology provides superior spatial resolution and an enhanced contrast-to-noise ratio, enabling precise characterization of small, subsolid nodules while significantly reducing the radiation dose—a key historical concern in broadening screening protocols.⁴ The ability to acquire high-fidelity images with lower radiation exposure mitigates a major barrier to expanding screening on a population level and may help address the high false-positive rates associated with conventional low-dose computed tomography (LDCT).

Therefore, we stand at a clinical crossroads. The rising tide of incidental findings is not a statistical curiosity; it is a clear signal that our current screening criteria are too narrow. We must advocate for a multipronged approach that includes removing legislative and administrative barriers for the currently eligible, as proposed by the bipartisan Increasing Access to Lung Cancer Screening Act.⁵ Concurrently, we must champion a data-driven expansion of the screening criteria themselves. Whether this evolves toward universal screening for a specific age demographic or, more likely, a selective broadening to include other validated high-risk groups remains a subject for debate and further research. However, until a viable biomarker-based screening test is fully validated and available, enhancing the awareness, accessibility, and eligibility criteria for LDCT scanning is our most potent weapon. We must transition from a reactive reliance on incidental discovery to a proactive strategy of intentional detection to truly impact mortality from this disease.

References

1. Zhou N, Deng J, Faltermeier C, et al. The majority of patients with resectable incidental lung cancers are ineligible for lung cancer screening. JTCVS Open. 2022;13:379-388. doi:10.1016/j.xjon.2022.11.021
2. Bandi P, Landy R, Star J, Kratzer TB, Smith RA, Jemal A. Lung cancer deaths prevented and life-years gained from lung cancer screening. JAMA. 2025;334(24):2225-2227. doi:10.1001/jama.2025.19798
3. US Preventive Services Task Force; Krist AH, Davidson KW, Mangione CM, et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962-970. doi:10.1001/jama.2021.1117
4. NAEOTOM Alpha with Quantum Technology. Siemens Healthineers. Accessed July 7, 2026. https://www.siemens-healthineers.com/en-us/computed-tomography/naeotom/naeotom-alpha
5. Increasing Access to Lung Cancer Screening Act, HR 6178, 119th Cong (2025). Accessed July 7, 2026. https://www.congress.gov/bill/119th-congress/house-bill/6178